The Pursuit of Redosable Gene Therapies for Hemophilia With Dr. Doug Kerr
Larry Luxner, senior correspondent for Rare Disease Advisor, interviews Doug Kerr, MD, PhD, chief medical officer at Generation Bio in Cambridge, Massachusetts. The company is aggressively pursuing redosable gene therapies for hemophilia and other rare diseases. Read the full article: Generation Bio Pursues Redosable Gene Therapy for Hemophilia A
